InnovAge (INNV) Competitors

$7.20 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$7.20 0.00 (0.00%)

As of 05/22/2026 04:10 PM Eastern

INNV vs. CON, VCYT, OPCH, LFST, and PRVA

Should you buy InnovAge stock or one of its competitors? MarketBeat compares InnovAge with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InnovAge include Concentra Group Holdings Parent (CON), Veracyte (VCYT), Option Care Health (OPCH), LifeStance Health Group (LFST), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.

How does InnovAge compare to Concentra Group Holdings Parent?

InnovAge (NASDAQ:INNV) and Concentra Group Holdings Parent (NYSE:CON) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Concentra Group Holdings Parent has a net margin of 7.97% compared to InnovAge's net margin of -1.22%. Concentra Group Holdings Parent's return on equity of 47.14% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Concentra Group Holdings Parent	7.97%	47.14%	6.48%

Concentra Group Holdings Parent has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Concentra Group Holdings Parent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A
Concentra Group Holdings Parent	$2.16B	1.49	$166.41M	$1.39	18.18

InnovAge has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Concentra Group Holdings Parent has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

InnovAge currently has a consensus target price of $7.00, suggesting a potential downside of 2.78%. Concentra Group Holdings Parent has a consensus target price of $30.25, suggesting a potential upside of 19.72%. Given Concentra Group Holdings Parent's stronger consensus rating and higher probable upside, analysts clearly believe Concentra Group Holdings Parent is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Concentra Group Holdings Parent	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Concentra Group Holdings Parent had 2 more articles in the media than InnovAge. MarketBeat recorded 2 mentions for Concentra Group Holdings Parent and 0 mentions for InnovAge. Concentra Group Holdings Parent's average media sentiment score of 0.84 beat InnovAge's score of 0.76 indicating that Concentra Group Holdings Parent is being referred to more favorably in the news media.

Company	Overall Sentiment
InnovAge	Positive
Concentra Group Holdings Parent	Positive

12.3% of InnovAge shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Comparatively, 8.1% of Concentra Group Holdings Parent shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Concentra Group Holdings Parent beats InnovAge on 15 of the 16 factors compared between the two stocks.

How does InnovAge compare to Veracyte?

Veracyte (NASDAQ:VCYT) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Veracyte presently has a consensus price target of $44.83, suggesting a potential downside of 0.44%. InnovAge has a consensus price target of $7.00, suggesting a potential downside of 2.78%. Given Veracyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veracyte is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Veracyte has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.95	$66.35M	$1.09	41.31
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A

12.3% of InnovAge shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 1.0% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Veracyte has a net margin of 16.25% compared to InnovAge's net margin of -1.22%. Veracyte's return on equity of 9.07% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
InnovAge	-1.22%	-4.73%	-2.20%

Veracyte has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Veracyte had 12 more articles in the media than InnovAge. MarketBeat recorded 12 mentions for Veracyte and 0 mentions for InnovAge. InnovAge's average media sentiment score of 0.76 beat Veracyte's score of 0.49 indicating that InnovAge is being referred to more favorably in the news media.

Company	Overall Sentiment
Veracyte	Neutral
InnovAge	Positive

Summary

Veracyte beats InnovAge on 13 of the 16 factors compared between the two stocks.

How does InnovAge compare to Option Care Health?

InnovAge (NASDAQ:INNV) and Option Care Health (NASDAQ:OPCH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

12.3% of InnovAge shares are held by institutional investors. Comparatively, 98.1% of Option Care Health shares are held by institutional investors. 1.0% of InnovAge shares are held by company insiders. Comparatively, 1.7% of Option Care Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Option Care Health has a net margin of 3.64% compared to InnovAge's net margin of -1.22%. Option Care Health's return on equity of 18.17% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Option Care Health	3.64%	18.17%	7.16%

InnovAge currently has a consensus price target of $7.00, indicating a potential downside of 2.78%. Option Care Health has a consensus price target of $31.25, indicating a potential upside of 49.31%. Given Option Care Health's stronger consensus rating and higher probable upside, analysts plainly believe Option Care Health is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Option Care Health	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Option Care Health had 13 more articles in the media than InnovAge. MarketBeat recorded 13 mentions for Option Care Health and 0 mentions for InnovAge. InnovAge's average media sentiment score of 0.76 beat Option Care Health's score of 0.45 indicating that InnovAge is being referred to more favorably in the media.

Company	Overall Sentiment
InnovAge	Positive
Option Care Health	Neutral

InnovAge has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Option Care Health has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Option Care Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A
Option Care Health	$5.65B	0.58	$207.59M	$1.29	16.22

Summary

Option Care Health beats InnovAge on 15 of the 17 factors compared between the two stocks.

How does InnovAge compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

LifeStance Health Group has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	2.01	$9.66M	$0.06	123.17
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A

In the previous week, LifeStance Health Group had 1 more articles in the media than InnovAge. MarketBeat recorded 1 mentions for LifeStance Health Group and 0 mentions for InnovAge. InnovAge's average media sentiment score of 0.76 beat LifeStance Health Group's score of 0.00 indicating that InnovAge is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeStance Health Group	Neutral
InnovAge	Positive

85.5% of LifeStance Health Group shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 3.2% of LifeStance Health Group shares are owned by company insiders. Comparatively, 1.0% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LifeStance Health Group presently has a consensus target price of $9.86, indicating a potential upside of 33.38%. InnovAge has a consensus target price of $7.00, indicating a potential downside of 2.78%. Given LifeStance Health Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe LifeStance Health Group is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

LifeStance Health Group has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

LifeStance Health Group has a net margin of 1.55% compared to InnovAge's net margin of -1.22%. LifeStance Health Group's return on equity of 1.56% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	1.55%	1.56%	1.07%
InnovAge	-1.22%	-4.73%	-2.20%

Summary

LifeStance Health Group beats InnovAge on 16 of the 17 factors compared between the two stocks.

How does InnovAge compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Privia Health Group has a net margin of 0.97% compared to InnovAge's net margin of -1.22%. Privia Health Group's return on equity of 2.81% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Privia Health Group	0.97%	2.81%	1.61%
InnovAge	-1.22%	-4.73%	-2.20%

Privia Health Group presently has a consensus price target of $31.23, indicating a potential upside of 37.04%. InnovAge has a consensus price target of $7.00, indicating a potential downside of 2.78%. Given Privia Health Group's stronger consensus rating and higher possible upside, research analysts clearly believe Privia Health Group is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

In the previous week, Privia Health Group had 4 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Privia Health Group and 0 mentions for InnovAge. Privia Health Group's average media sentiment score of 0.76 beat InnovAge's score of 0.76 indicating that Privia Health Group is being referred to more favorably in the media.

Company	Overall Sentiment
Privia Health Group	Positive
InnovAge	Positive

Privia Health Group has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12B	1.35	$22.92M	$0.16	142.44
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A

Privia Health Group has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, InnovAge has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

94.5% of Privia Health Group shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 5.7% of Privia Health Group shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Privia Health Group beats InnovAge on 16 of the 16 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INNV vs. The Competition

Export

Metric	InnovAge	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$977.30M	$8.38B	$6.46B	$12.34B
Dividend Yield	N/A	2.98%	2.76%	5.28%
P/E Ratio	-80.00	21.27	21.22	25.66
Price / Sales	1.14	19.11	562.28	86.31
Price / Cash	N/A	86.20	43.49	56.67
Price / Book	4.21	5.84	10.31	7.14
Net Income	-$30.31M	$183.47M	$3.57B	$335.98M
7 Day Performance	-0.14%	64.18%	6.43%	4.15%
1 Month Performance	-9.43%	49.96%	3.57%	2.54%
1 Year Performance	83.21%	4.53%	34.07%	35.06%

InnovAge Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INNV InnovAge	1.2681 of 5 stars	$7.20 flat	$7.00 -2.8%	+83.2%	$977.30M	$853.70M	N/A	2,440	Gap Up
CON Concentra Group Holdings Parent	4.1236 of 5 stars	$25.57 +2.3%	$30.25 +18.3%	+19.5%	$3.27B	$2.16B	18.39	13,133
VCYT Veracyte	1.9448 of 5 stars	$39.56 -0.4%	$44.83 +13.3%	+65.8%	$3.16B	$517.15M	36.29	790
OPCH Option Care Health	4.9102 of 5 stars	$19.59 -1.2%	$31.25 +59.5%	-33.4%	$3.08B	$5.65B	15.19	8,266	Gap Up High Trading Volume
LFST LifeStance Health Group	3.7222 of 5 stars	$7.93 +3.4%	$10.00 +26.1%	+34.6%	$3.08B	$1.42B	132.17	10,961	Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INNV) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InnovAge (INNV) Competitors

INNV vs. CON, VCYT, OPCH, LFST, and PRVA

How does InnovAge compare to Concentra Group Holdings Parent?

Summary

How does InnovAge compare to Veracyte?

Summary

How does InnovAge compare to Option Care Health?

Summary

How does InnovAge compare to LifeStance Health Group?

Summary

How does InnovAge compare to Privia Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InnovAge (INNV) Competitors

INNV vs. CON, VCYT, OPCH, LFST, and PRVA

How does InnovAge compare to Concentra Group Holdings Parent?

Is INNV or CON more profitable?

Which has better earnings & valuation, INNV or CON?

Which has more risk and volatility, INNV or CON?

Do analysts rate INNV or CON?

Does the media refer more to INNV or CON?

Do institutionals & insiders have more ownership in INNV or CON?

Summary

How does InnovAge compare to Veracyte?

Do analysts prefer VCYT or INNV?

Which has preferable valuation and earnings, VCYT or INNV?

Do insiders & institutionals hold more shares of VCYT or INNV?

Is VCYT or INNV more profitable?

Which has more volatility & risk, VCYT or INNV?

Does the media prefer VCYT or INNV?

Summary

How does InnovAge compare to Option Care Health?

Do institutionals and insiders believe in INNV or OPCH?

Is INNV or OPCH more profitable?

Do analysts prefer INNV or OPCH?

Does the media favor INNV or OPCH?

Which has more risk and volatility, INNV or OPCH?

Which has higher valuation & earnings, INNV or OPCH?

Summary

How does InnovAge compare to LifeStance Health Group?

Which has stronger valuation & earnings, LFST or INNV?

Does the media refer more to LFST or INNV?

Do institutionals & insiders believe in LFST or INNV?

Do analysts recommend LFST or INNV?

Which has more risk and volatility, LFST or INNV?

Is LFST or INNV more profitable?

Summary

How does InnovAge compare to Privia Health Group?

Is PRVA or INNV more profitable?

Do analysts recommend PRVA or INNV?

Does the media prefer PRVA or INNV?

Which has better earnings and valuation, PRVA or INNV?

Which has more volatility and risk, PRVA or INNV?

Do insiders & institutionals believe in PRVA or INNV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools